does blue cross blue shield cover glp 1 of Massachusetts will stop covering popular drugs for weight loss. Here's why Breaking GLP-1 NEWS!!! Blue Cross

If you take somebody and intervene early, Im a big fan of preventative medicine

Tirzepatide (Mounjaro, Zepbound): A Dual GLP-1/GIP Receptor Agonist for Weight Loss and Diabetes Control In May 2022, tirzepatide was approved for diabetes management under the name Mounjaro, and the FDA expanded this approval to weight loss under the brand name Zepbound in November 2023 (owned by the pharmaceutical company Lilly)

A randomized control trial by Khodabakhshi et al

In the current study, we performed a nested, case-control study to explore the association between serum LC levels and the risk of cancer incidence, by drawing data from a community-based population in China

Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]

Huang et al., 2025) (Fig